Advertisement

Advertisement
Breast Cancer
Survivorship

Intervention to Promote Breast Cancer Surveillance in Childhood Cancer Survivors Who Received Chest Radiotherapy

In the EMPOWER trial, which took place within the larger Childhood Cancer Survivor Study (CCSS) and was reported in the Journal of Clinical Oncology, Oeffinger et al found that an intervention consisting of mailed educational materials followed by telephone-delivered counseling led to an increased use of screening mammography among survivors who had received chest radiotherapy for childhood cancer. The use of screening magnetic resonance imaging (MRI) was not increased.

Leukemia

Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia

In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia.

Colorectal Cancer
Pain Management

ESMO World GI: Findings From the BEACON CRC Trial and More

In this episode of The ASCO Post Podcast, we discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer...


Advertisement
Issues in Oncology

An ASCO Survey, Hope, and Conventional Therapies

How do you respond when patients with a good prognosis want to delay chemotherapy to try an anticancer diet for a few months or visit an unregulated clinic for unproven therapies? I’m asking because of an alarming finding of ASCO’s 2018 National Cancer Opinion Survey: “Nearly 4 in 10 Americans believe cancer can be cured solely through alternative therapies….” Clearly, we have a problem in today’s discussion about cancer treatments. What can clinicians do?

Multiple Myeloma

How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy

Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected to die from the disease in 2019. Now, chimeric antigen receptor (CAR) T-cell therapy, which has been shown to induce durable remissions and even cures in some patients with acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma, may be the next breakthrough in the treatment of multiple myeloma, especially for patients with highly refractory disease.

Advertisement




More Top Stories

Colorectal Cancer

Thomas J. George, MD, on Locally Advanced Rectal Cancer: Total Neoadjuvant Therapy

Erratum

In the June 10, 2019, issue of The ASCO Post, a photo on page 69, in an article about the National Comprehensive Cancer Network Board of Directors, was incorrectly identified as Ronald Walters, MD, of The University of Texas MD Anderson Cancer Center. The photo was actually of Roland B. Walter,...

Advertisement

Subtypes of Pancreatic Neuroendocrine Tumors and Effect on Disease Recurrence

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors (pNETs) associated with different risks of recurrence following surgical treatment. The finding could yield predictive tests while focusing vigilant follow-up monitoring on patients with pNETs that have a higher...

Pancreatic Cancer

Alok A. Khorana, MD, and Hedy L. Kindler, MD, on Metastatic Pancreatic Cancer: POLO Trial on Olaparib as Maintenance Therapy

Supportive Care
Palliative Care

Improve Quality of Life With This Palliative Care Education Resource for Your Patients

Do your patients know that supportive care can help them manage their symptoms and side effects, regardless of age, cancer type, or disease stage? Make sure your patients understand the benefits of palliative care and where to access services with the ASCO Answers Palliative Care booklet. Your...

Supportive Care
Palliative Care

Improve Quality of Life With This Palliative Care Education Resource for Your Patients

Do your patients know that supportive care can help them manage their symptoms and side effects, regardless of age, cancer type, or disease stage? Make sure your patients understand the benefits of palliative care and where to access services with the ASCO Answers Palliative Care booklet. Your...

Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-Term Survivors of Childhood ALL

In a study reported in JAMA Oncology, Banerjee et al found that higher cumulative anesthesia exposure and duration of exposure during treatment of childhood acute lymphoblastic leukemia (ALL) may be associated with adverse neurocognitive and abnormal neuroimaging outcomes in long-term survivors....

Multiple Myeloma
Issues in Oncology

Kamal Chamoun, MD, on Multiple Myeloma: Insurance Status and Survival

Pancreatic Cancer

APACT Trial: Nab-paclitaxel/Gemcitabine vs Gemcitabine Alone in Adjuvant Treatment of Pancreatic Cancer

The largest adjuvant trial in pancreatic adenocarcinoma, the global phase III APACT trial, evaluated the combination of adjuvant nab-paclitaxel/gemcitabine vs gemcitabine monotherapy in patients with resected pancreatic cancer. Results of the study were reported by Margaret A. Tempero, MD, of the...

Advertisement

Is There an Increased Long-Term Risk for Ovarian Cancer After Assisted Reproductive Technology?

Fertility treatment is not associated with an increased long-term risk of ovarian cancer, according to the results of a large-scale multicenter study presented by Spaan et al at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (Abstract O-183). The findings,...